作为抗癌剂的循环素依赖性激酶的小分子新兴抑制剂
Nitin Srivastava1, Anil Kumar Saxena2
1Department of Chemistry, Amity University Uttar Pradesh Lucknow Campus, 226028, Lucknow, India.
Current medicinal chemistry
|June 5, 2025
概括
循环素依赖激酶 (CDK) 是细胞循环的关键调节者和癌症标. 本次综述强调了具有 CDK 抑制和抗癌潜力的小分子,特别是异环,用于开发新的癌症治疗药物.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药用化学 医学化学
背景情况:
- 循环素依赖激酶 (CDK) 调节细胞循环的进展,影响转录,新陈代谢和亡.
- CDKs的失调与癌症有关,这使得它们成为化疗药物的关键标.
- 特定的环林和CDK作为检查点,确保精确的DNA复制并诱导缺陷细胞的亡.
研究的目的:
- 审查最近 (过去十年) 的具有CDK抑制和抗癌活性的小分子.
- 为设计新型CDK抑制剂提供化学结构的概述.
- 确定有前途的分子类,以改善癌症治疗方法.
主要方法:
- 使用科学数据库 (PubMed,科学直接,谷歌学者等) 进行全面的文献搜索. ) 的情况.
- 对表现出CDK抑制和抗癌性质的小分子发表的研究分析.
- 基于化学类别和观察到的CDK抑制概况的分子分类.
主要成果:
- 异循环,宏循环和天然产品是具有抗癌活性的有希望的CDK抑制剂.
- 对于抗癌作用,CDK4/6抑制最为显著,但也观察到CDK1,2,7和9的抑制.
- 几种分子在各种癌症细胞系中表现出强大的CDK抑制和抗癌活性,其中一些进展到临床试验.
结论:
- 小分子,特别是异环,显示出作为癌症治疗的CDK抑制剂的显著潜力.
- 需要进一步的结构调制,以开发更具特异性和选择性的CDK抑制剂.
- CDK4/6抑制剂在组合疗法中表现有希望,例如与乳腺癌的放射治疗,具有可控的毒性.
相关概念视频
02:34Inhibition of Cdk Activity
5.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.6K
02:15M-Cdk Drives Transition Into Mitosis
6.3K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.3K
02:39Positive Regulator Molecules
6.5K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.5K
01:45Positive Regulator Molecules
134.4K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
134.4K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:10Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K